by Rod Raynovich | Jan 26, 2011 | BIOgraph
The melt-up resumes. Everyone talks about the really big correction but all we get is a measly 2-3% hit then onward and upward. Metals and materials were ~2% winners today and the NAZ was up 0.75%. Titanium (TIE) was up 7.9 % . What’s with that? Although...
by Rod Raynovich | Jan 26, 2011 | Energy, Weather//Ski Reports-Western US
High and Dry in the West Why am I reporting on snow? There is none and little hope for the next seven days-maybe longer. If you like cool sunny dry weather come to SoCal.If you like snow go to NYC or Vancouver BC.I am booking MT for mid-February. Mammoth Lakes...
by Rod Raynovich | Jan 25, 2011 | BIOgraph
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic...
by Rod Raynovich | Jan 24, 2011 | BIOgraph, Reading List
Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET...
by Rod Raynovich | Jan 24, 2011 | BIOgraph
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December...
by Rod Raynovich | Jan 21, 2011 | BIOgraph, Reading List
Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B. Medical Device was flat year over year with $2.3B invested. ANNUAL...
by Rod Raynovich | Jan 21, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX,...
by Rod Raynovich | Jan 19, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down...
by Rod Raynovich | Jan 18, 2011 | BIOgraph
J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel....
by Rod Raynovich | Jan 18, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the...
